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Abstract TopBP1 (topoisomerase IIβ binding protein 1) pro-
tein is involved in DNA replication, DNA damage checkpoint
response and transcriptional regulation. In this study we in-
vestigated whether alterations in the TopBP1 gene can influ-
ence the risk of endometrial cancer. We examined the associ-
ation between five single nucleotide polymorphisms
(rs185903567, rs116645643, rs115160714, rs116195487,
and rs112843513) located in the 3′UTR region of the
TopBP1 gene and endometrial cancer risk as well as allele-
specific gene expression. One hundred twenty-one endome-
trial cancer patients were genotyped for these SNPs. Allele-
specific TopBP1 mRNA and protein expressions were deter-
mined by real time PCR and western blotting methods, re-
spectively. Only one SNP (rs115160714) showed an associa-
tion with endometrial cancer. Compared to homozygous com-
mon allele carriers, heterozygous for the T variant had signif-
icantly increased risk of endometrial cancer [adjusted odds
ratio (OR)=5.59, 95 % confidence interval (CI): 1.96–15.91,
p=0.0003]. Mean TopBP1 mRNA and protein expression
were higher in the individuals with the CT genotype. There
was a significant association between the rs115160714 and
tumor grade and FIGO classification. Most carriers of minor
allele had a high grade tumors (G3) classified as FIGO III/IV.
The results of our study raise a possibility that a genetic
variation of TopBP1 may be implicated in the etiology of
endometrial cancer.
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Introduction
Endometrial cancer is the most common malignancy of the
female reproductive tract. It accounts each year for approxi-
mately 142.000 new cases diagnosed worldwide, and for
42.000 deaths. Endometrial cancer is the seventh most com-
mon malignant disorder and its incidence is expected to in-
crease in the near future due to the increase in life span
expectancy and obesity [1]. However, despite great progress
in the endometrial cancer studies, the molecular mechanisms
that contribute to endometrium carcinogenesis remain poorly
understood. Thus, there is a necessity to identify all endome-
trial cancer susceptibility genes.
The latest international prospective cohort study showed
that risk of endometrial cancer is higher in BRCA1 mutation
carriers than in the general population [2]. TopBP1 (topoisom-
erase IIβ binding protein 1) protein displays structural and
functional similarities with BRCA1 and is involved in DNA
replication, DNA damage checkpoint response and transcrip-
tional regulation. TopBP1 gene comprising 28 exons in locat-
ed on chromosome 3q22.1 and encodes a 1522 amino acid
proteins [3]. The most characteristic feature of TopBP1 is that
it has eight BRCT (BRCA1 C-terminal) domains [4, 5]. These
domains are involved in interaction with other proteins as well
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as in interaction with single and double-stranded DNA [6].
The C-terminal region of TopBP1 containing two BRCTs is
responsible for interaction with topoisomerase. Following
ionizing radiation, TopBP1 is recruited to DNA breaks and
co-localizes with Nbs1 (Nijmegen breakage syndrome 1),
BRCA1 and 53BP1 (p53-binding protein 1) in nuclear foci.
TopBP1 and BRCA1 also co-localize with proliferating cell
nuclear antigen (PCNA) at stalled replication forks after a
replication block [3]. TopBP1 has been established as an
essential activator of ATR (ATM and RAD3-related) kinase.
ATR plays a crucial role in maintenance of genomic integrity
by delaying cell division in the presence of DNA damage or
replication stress [7].
The results of our earlier studies showing association be-
tween TopBP1 polymorphism and breast cancer risk prompted
us to investigate whether such genetic alterations can influence
the endometrial cancer risk. In present study we tested the effect
of five SNPs [rs185903567 (G/A), rs116645643 (A/G),
rs115160714 (C/T), rs116195487 (C/G), and rs112843513
(C/delC)] in the 3′UTR (3′untranslated region) of TopBP1 gene
on endometrial cancer risk as well as on allele-specific




This study involved 121 women with endometrial carcinoma
(age range 31–84, mean age 63.84±10.24) recruited between
March 2009 and December 2012. The patients had a con-
firmed diagnosis of endometrial carcinoma based on histo-
pathological evaluation and were under treatment at the
Clinical Division of Gynecological Oncology, Medical
University of Łódź. None of the recruited patients received
preoperative chemo- or radiotherapy. Patients diagnosed with
previous endometrial tumors or with tumors located elsewhere
were excluded. The clinical stage of the disease was defined
according to the FIGO criteria. Histological grade was based
on the degree of glandular differentiation, and tumors were
graded as: G1 (percentage of solid growth in the tumor mass
up to 5 %); G2 (percentage of solid growth between 6 and
50 %); G3 (percentage of solid growth above 50 %). The
depth of myometrial invasion was defined as the percentage of
the myometrium invaded by the tumor. The distributions of
sociodemographic characteristics and clinical characteristics
of the patients are shown in Table 1.
As a control in the study of polymorphisms we used the
results obtained and published earlier for a group of 556
healthy Polish individuals [8]. They were collected from the
hospital routine controls of health and used as control. They
were non-related women, that have never been diagnosed with
endometrial tumors, other tumors or chronic disease and were
randomly selected and frequency matched to the cases on age
(age range 34–83, mean age 51.27±11.18).
Informed consent was obtained from patients and controls,
and the Ethical Committee approved the study.
DNA Extraction and Genotyping
Each genomic DNA sample was extracted from endometrial
cancer tissues and peripheral blood samples using FlexiGene®
DNA Kit (Qiagen GmbH, Hilden, Germany). DNA concentra-
tion was determined by spectrophotometry using the Helios
Alpha UV–Vis spectrophotometer system (Thermo Fisher
Scientific Inc.). The absorbances at 230, 260 and 280 nm were
measured on 2 μl of each sample. Concentration of DNA was
estimated by spectrophotometric quantification at 260 nm. The
overall purity was assessed by calculating the absorbance ratios
260/280 and 260/230. High values for both ratio (260/280>1.8,
260/230>2) are commonly accepted as good indicators for pure
DNA. The single nucleotide polymorphisms (SNPs)
rs185903567 (G/A), rs116645643 (A/G), rs115160714 (C/T),
rs116195487 (C/G), rs112843513 (C/delC) located at the 3′UTR
of TopBP1 gene were evaluated (http://www.ensembl.org/
Homo_sapiens/Gene/Sequence?db=core;g=ENSG00
000163781;r=3:133317019-133380737). These polymorphisms
were analyzed by ASO-PCR (rs185903567, rs116645643,
rs116195487) and RFLP-PCR (rs115160714, rs112843513).
ASO-PCR Assays
Mutated or wild-type sequences were specifically amplified in
a noncompetitive PCR reaction performed on DNA in 50 μL
Table 1 Selected base-
line characteristics of en-
dometrial cancer cases
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reaction mixture and PCR conditions as described below,
using allele-specific and reverse primers as follows: for the
rs185903567 SNP, F wildtype: 5′-TGAAGAATTCTGCTTC
AGTA-3′ or F mutant: 5′-TGAAGAATTCTGCTTCAGTG-
3′ and R: 5′- TTACAATTTCAGGTGTTCAAA-3′ (annealing
at 57 °C; 64-bp PCR product); for the rs116645643 SNP, F
wildtype: 5′-AAAGTTACCTGAAATAACAACTA-3′ or F
mutant: 5′-AAAGTTACCTGAAATAACAACTG-3′ and R:
5′- AATGTGGTTTAACAGCAAGC-3′ (annealing at 55 °C;
61-bp PCR fragment); for the rs116195487 SNP, F wildtype:
5′-CTTGCTGTTAAACCACATTGAAGAG-3′ or F mutant:
5′-CTTGCTGTTAAACCACATTGAAGAC-3′ and R: 5′-
TCATTAAACCTTGTGCTCAG-3′ (annealing at 58.5 °C;
234-bp PCR fragment). The sensitivity of this assay was
determined for each mutation by amplification of 10-fold
limited dilutions of 100 ng patient’s DNA at time of resistance
in 100 ng healthy control DNA.
RFLP-PCR Assay
PCR reactions were performed, using Perkin-Elmer DNA
Thermal cycler 480, in a total volume of 50 μl to amplify
TopBP1 rs115160714, rs112843513. The reaction mixtures
consisted of 100 ng of genomic DNA and the following set of
primers: 10 μM of rs115160714 primers (5′-CCCTTCTTGA
GTTTTGAACACC-3′ and 5′-AAAGCAAAATCCATTACC
TTGC-3′), rs112843513 primers (5′-GCCTGAGCACAAGG
TTTAATG-3′ and 5′-ACAGATGCCAGGGTGCTC-3′). The
DNA samples were amplified in the presence of 200 μmol
dNTPs, 10 % dimethylsulfoxide, 1 x Taq polymerase buffer,
1.5 mM MgCl2 and 0.5U AmpliTaq Gold (PE Applied
Biosystems, Foster, CA). The PCR condition for
rs115160714 and rs112843513 comprised an initiation dena-
turation step at 94 °C for 4 min, followed by 30 cycles of
96 °C for 1 min, 59 °C for 1 min, 72 °C for 1 min and final
extension step at 72 °C for 10 min. Subsequently, RFLP
analysis was performed on 20 microliters each of the respec-
tive PCR products by subjecting them to the following restric-
tion enzymes: at a 5U concentration: BseRI (at 37 °C for 3 h)
for rs115160714 and RasI (at 37 °C for 16 h) for rs112843513
(both from New England Biolabs, UK).
In the case of rs115160714 the lengths of fragments ob-
tained by digestion of each 211-bp fragment by BseRI were
84 bp and 127 bp for wild type, and 211 bp for mutant type.
For rs112843513, the lengths of fragments obtained by diges-
tion of each 211-bp fragment by RasI were 71 bp and 140 bp
for wild type, and 211 bp for mutant type.
The products were analyzed by electrophoresis on 3 %
agarose gels and ethidium bromide-stained. Positive and neg-
ative controls were included in each gel. Quality control was
ensured by including a random 5 % of the samples as
duplicates.
Total RNA Extraction and cDNA Synthesis
Total RNA was extracted from endometrial cancer tissues
using TRI Reagent® (Sigma Aldrich Corp. St. Louis, MO,
USA) according to manufacturer’s protocol. RNAwas eluted
in 20 μl RNase-free water, quantified by spectrophotometry at
260 nm and stored at -20 °C. RNAwith a 260/280 nm ratio in
range 1.8–2.0 was considered high quality. First-strand
cDNAs were obtained by reverse transcription of 1 μg of total
RNA using RevertAidTM First Strand cDNA Synthesis Kit
(Fermentas UAB, Vilnius, Lithuania) following the manufac-
turer’s protocol.
Real Time Quantitative PCR
For real-time PCR analysis of TopBP1 mRNA in pathological
tissues, TaqMan® Gene Expression Assays (Applied
Biosystems, Bedford, MA, USA) were used according to the
manufacturer’s instruction. Before starting the real-time PCR
analysis we used the NormFinder algorithm to select the best
reference gene (http://www.mdl.dk). We chose GAPDH
(glyceraldehyde 3-phosphate dehydrogenase) gene because
it had the lowest stability value - 0.017. The fluorogenic,
FAM labeled probes and the sequence specific primers for
TopBP1 and GAPDH were obtained as inventoried assays
Hs00199775_m1 and Hs99999905_m1, respectively
(Applied Biosystems, Bedford, MA, USA). The reactions
were performed in duplicate. A positive result was defined
by a threshold cycle (Ct) value lower than 40 (the Ct value is
determined by the number of cycles needed to exceed the
background signal). Ct value of all positive results were lower
than 30. Abundance of TopBP1 mRNA in studied material
was quantified by the ΔCt method. ΔCt (CtTopBP1-CtGAPDH)
values were recalculated into relative copy number values
(number of copies of TopBP1 mRNA per 1000 copies of
GAPDH mRNA).
Western Blotting Analysis
Tissue homogenate was obtained from each sample in the
presence of the serine protease inhibi tor PMSF
(phenylmethylsulfonyl fluoride) and 10 mM sodium molyb-
date. The protein content was estimated by modified Lowry
method using bovine serum albumin as standard. Homogenate
proteins (50 μg protein/lane) were resolved by 8 % SDS-
PAGE and electroblotted onto Immobilon-P transfer mem-
branes (Millipore, Bedford, MA, USA). The blots were incu-
bated 1 h with rabbit polyclonal anti-TopBP1 (Abcam,
Cambridge, UK) in a 1:1000 dilution. After being washed
three times with TBST (Tris buffered saline with Tween-20),
the membranes were incubated 1 h with goat anti-rabbit
antibodies conjugated with horseradish peroxidase (1:5000
dilution). The membranes were again washed three times with
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TBST and incubated with peroxidase substrate solution (3,3′-
diaminobenzidine -DAB). Gel-Pro® Analyzer software
(Media Cybernetics Inc., Bethesda, MD, USA) was used for
densitometry analysis of protein bands. The integrated optical
density (IOD) of the bands, in a digitized picture, was
measured.
Quality Control
For quality control purposes, 10 % of samples were randomly
selected, and sequence analysis performed, with 100 % con-
cordance to the genotype. Laboratory personnel were unable
to distinguish among case, control, and quality control
samples.
Statistical Data Analysis
Genotype distributions were evaluated for agreement with
Hardy–Weinberg equilibrium by the chi-square test.
Unconditional multiple logistic regression models were used
to calculate odds ratios (ORs) and 95 % confidence intervals
(CIs) for the association of genotype with endometrial cancer
risk. Genotype data were analyzed with the homozygote of the
common allele as the reference group. Variants of homozy-
gotes and heterozygotes were combined to evaluate the dom-
inant effect. For each SNP, trend tests were conducted by
assigning the ordinal values 1, 2, and 3 to homozygous
wild-type, heterozygous, and homozygous variant genotypes,
respectively, and by adding these scores as a continuous
variable in logistic regression model. All multivariate models
were adjusted for age, family history, obesity, smoking status,
parity, menopausal status, and use of contraceptive and men-
opausal hormones. Since levels of TopBP1 mRNA and pro-
tein expression in studied material specimens did not show
normal distribution (Kolmogorov-Smirnov test) the non-
parametrical statistical tests (Mann–Whitney U test, Kruskal-
Wallis test with post hoc multiple comparisons or the
Spearman rank correlation test) were applied. The chi square
test was used to identify relationship between positive expres-
sion of TopBP1 and clinicopathological parameters. Reported
p-values were two-sided. Probabilities were considered sig-
nificant whenever p-value was lower than 0.05. All analyses
were completed using SAS software (version 9.0 SAS
Institute, Cary, NC, USA).
Table 3 Adjusted odds ratio for
relation between TopBP1 geno-
types and different tumor grades
and FIGO classifications
* p value for additive models
a Adjusted for age
Variables Grade (n, %) OR (95 % CI)a p*
Low grade (n=102) High grade (n=19)
CC 100 (98.0) 12 (63.1) 1.00 (ref.)
CT 2 (2.0) 6 (31.5) 25.17 (3.68–170.43) 0.0001
TT 0 (0.0) 1 (5.4) − −
C 200 (99.5) 30 (78.9) 1.00 (ref.)
T 4 (0.5) 8 (21.1). 13.24 (3.5–50.57) 0.0001
FIGO classification (n, %)
FIGO I/II (n=96) FIGO III/IV (n=25)
CC 92 (95.8) 20 (80.0) 1.00 (ref.)
CT 4 (4.2) 4 (16.0) 4.61 (1.05–20.71) 0.03
TT 0 (0.0) 1 (4.0) − −
C 188 (97.9) 44 (88.0) 1.00 (ref.)
T 4 (2.1) 6 (12.0) 6.43 (1.75–23.57) 0.005
Table 2 Frequency distribution
of the TopBP1 genotypes/alleles
in cases and controls, and the risk
of endometrial cancer
* p value for additive models
a Adjusted for age
b Testing additive genetic model
(Cochran-Armitage test for trend)
c Testing dominant genetic model
d Testing recessive genetic model
Variables Cases (%)/Controls (%) OR (95 % CI)a p*
rs115160714
C/C 112 (92.6)/548 (98.6) 1.00 (ref.) 0.0003
C/T 8 (6.6)/7 (1.2) 5.59 (1.96–15.91) 0.21
T/T 1 (0.8)/1 (0.2) 4.89 (0.30–79.23)
C 232 (99.2)/1103 (99.2) 1.00 (ref.)
T 10 (7.4)/9 (0.8) 5.28 (2.12–13.14) 0.0001
p- trendb 0.0003
C/T or T/T vs. C/Cc 5.50 (2.05–14.74) 0.0001
C/T or C/C vs. T/Td 4.62 (0.29–74.46) 0.28
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Results
Genotypes and Genotypic Distribution in Patients and Control
Subjects
Genotype distributions for TopBP1 polymorphisms in 121
endometrial cancer patients and 556 control subjects are sum-
marized in Table 2. Three SNPs (rs185903567, rs116195487,
and rs112843513) were not observed in the 3′UTR of TopBP1
gene in our studied controls and cases. The rs116645643 was
observed only in control group, but it was not included in the
further analyzes. For the control group, rs116645643 poly-
morphism was in Hardy-Weinberg equilibrium (p=0.86).
All cases and controls were common allele carriers. Only
one SNP (rs115160714) showed an association with endome-
trial cancer. The tested SNP did not follow the Hardy-
Weinberg equilibrium for control group. The minor allele
frequencies among the controls were consistent with those
of the general population, as found in the NCBI dbSNP
databases. The minor allele frequencies of rs115160714 were
less than 5 %. The frequency of individuals who carried (T)
allele was significantly higher in cases group (7.4 %) than in
control group (0.8 %; p<0.0001). Compared to homozygous
common allele carriers, heterozygous for the T variant were
found to be at a significant 5.59-fold increased risk of breast
cancer (95 % CI=1.96–15.91; p=0.0003).
Association of rs115160714 with Clinical and Environmental
Parameters
Of the 121 endometrial cancer patients, 102 (84.3 %) had a
low-grade tumor (grades G1 and G2), and 19 (15.7 %) had a
high-grade tumor (G3). Most tumors, (96–79.3 %) were clas-
sified as FIGO I and II, and the remaining 25 (20.7 %) were
FIGO III/IV (Table 3). There was a significant association
between CT genotype and tumor grade or FIGO classification.
Most carriers of minor allele had a high-grade tumors classi-
fied as FIGO III/IV (Table 3).
Association Between TopBP1 Genotypes and mRNA/Protein
Expression in Endometrial Cancer Tissue
We found that mean TopBP1 mRNA expression was lower in
the case of individuals with the CC genotype than in case of
minor allele carriers, i.e. CT heterozygotes and TT homozy-
gotes (308.0±117.0, 582.3±142.0 and 673.6±132.6 copies of
TopBP1 mRNA per 1000 copies of GAPDH mRNA, respec-
tively, p<0.05 for all comparisons) (Table 4, Fig 1a). We found
TopBP1 protein expression in 81.2 %, 75.0 % and 0.0 % of
endometrial cancer tissue homogenate samples of CC, CT, and
TT genotype carriers, respectively. Although the protein ex-
pression was more frequently observed in common allele car-
riers group, the mean expression level was lower than in minor
allele carriers (122.4±36.7, 215.1±43.2, 189.3±21.5 IOD rel-





































Fig. 1 The relationship between
TopBP1 mRNA and protein
expression and the rs115160714
genotype in endometrial cancers.
a Expression of TopBP1 gene
measured by real-time PCR in
relation to genotype. bWestern
blotting analysis of TopBP1
expressionmeasured in relation to
genotype. Figure shows the
representative results of TopBP1
immunodetection in endometrial
cancer tissue homogenates (50 μg
protein per lane)
Table 4 Comparison of TopBP1 mRNA and protein expression in





TopBP1mRNA expression [copies of
TopBP1mRNA per 1000 copies of
GAPDHmRNA]
pa
CC 96/112 (85.7) 308.0±117.0
CT 7/8 (87.5) 582.3±142.0 0.006






[Integrated Optical Density (IOD)
relative units] homogenate fraction
pa
CC 91/112 (81.2) 122.4±36.7
CT 6/8 (75.0) 215.1±43.2 0.018
TT 0/1 (0.0) 189.3±21.5 0.043
Results are given as mean ± standard error
a Differences between the three groups were evaluated with Kruskal-
Wallis test with post hocmultiple comparisons
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Fig 1b). There was a statistically significant correlation between
TopBP1 mRNA and protein expressions (Spearman correlation
coefficient for CC and CT genotype 0.67 and 0.70, respectively,
p<0.05 for all comparisons). However, not in all cases with
positive mRNA expression we could detected TopBP1 protein.
BothmRNA and proteinwas detected in 73 of 112CC samples,
in 5 of 8 of CT samples and 0 of 5 TT samples.
Discussion
The DNA damage checkpoint is a signal transduction path-
way that monitors the integrity of the DNA, prevents cell
cycle progression and promotes appropriate DNA metabo-
lism. Failure to trigger the DNA damage checkpoint leads to
genome instability, one emerging hallmark of cancer. The
ATM (ataxia telangiectasia mutated) and ATR (ATM and
RAD3-related) kinases are two key DNA damage sensors.
TopBP1 has been established as an essential activator of ATR.
TopBP1 may regulate the activation of ATR-Chk1 checkpoint
signaling at several levels i.e. TopBP1 is a direct activator of
ATR kinase activity, TopBP1 acts as a scaffold for all neces-
sary proteins for ATR activation, TopBP1 can regulate late
stage of the DNA damage checkpoint by facilitating Chk1
phosphorylation and activated ATR [7].
There are only a few studies concerning the role of muta-
tion in genes involved DNA damage checkpoint response in
endometrial cancers. The results showed that ATR and BRCA1
were frequently mutated in endometrial cancer patients [9].
Mutations in ATR were associated with biologic aggres-
siveness as evidenced by reduced disease-free and over-
all survival [10].
The biological functions of TopBP1 protein as well as its
close similarity with BRCA1 prompted us to investigate
whether alterations in TopBP1 gene can influence the risk of
endometrial cancer. To our knowledge, there is no literature
data on TopBP1 and endometrial cancer. Our earlier studies
concerning TopBP1 in breast cancer showed association be-
tween SNP (rs115160714) with breast cancer risk as well as
aberrant expression of this protein in breast cancer. Our find-
ings suggested that increased level of TopBP1 protein might be
associated with progression of hereditary breast cancer [11].
In this study, we demonstrated that out of five studied
polymorphisms in the 3′UTR region of TopBP1 gene only
one, the rs115160714 was significantly associated with endo-
metrial cancer risk. Compared to homozygous common allele
carriers, heterozygous for the T variant were found to be at a
highly significant 5.59 -fold increased risk of developing
endometrial cancer (95 % CI=1.96–15.91; p=0.0003). This
results are similar to that obtained earlier for breast cancer
(OR=3.54 (95 % CI=1.56–8.39; p=0.002) [8].
We found out that mean TopBP1 mRNA and protein levels
were higher in case of individuals with CT genotype. We do not
know the reason of this correlation. However, studied SNP
(rs115160714) is located at the 3′UTR region TopBP1 gene
which may cause higher production of mRNA. The other ex-
planation is that this SNP change the half-life of mRNA leading
to grater TopBP1 protein level. Since the rs115160714 is located
in miRNAs (miR-3138, miR-4302 and miR-1207-5p) binding
site, increased level of TopBP1 mRNA might possibly results
from altered posttranscriptional regulation of gene expression.
The studies of Liu et al. [12] showed that TopBP1 plays a
role in repressing of p53. TopBP1 interacts with p53 binding
domain and inhibits the promoter binding activity of p53.
Thus, increased expression of TopBP1 may cause deregula-
tion of this important tumor suppressor protein and contribute
to cancer development or progression.
In conclusion, our results showed that rs115160714 is
associated with increased expression of TopBP1 and endome-
trial cancer risk.
Open Access This article is distributed under the terms of the Creative
Commons Attribution License which permits any use, distribution, and
reproduction in any medium, provided the original author(s) and the
source are credited.
References
1. Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E,
Vergote I (2005) Endometrial cancer. Lancet 366:491–505
2. Segev Y, Iqbal J, Lubinski J et al (2013) Hereditary Breast Cancer
Study Group. The incidence of endometrial cancer in women with
BRCA1 and BRCA2 mutations: an international prospective cohort
study. Gynecol Oncol. doi:10.1016/j.ygyno.2013.03.027
3. Forma E, Bryś M, Krajewska W (2011) TopBP1 in DNA damage
response. In: Kruman I (ed) DNA repair/book 4. INTECH Open
Access, Rijeka, pp 281–304
4. Glover JNM (2006) Insights into the molecular basis of human
hereditary breast cancer from studies of the BRCA1 BRCT domain.
Fam Cancer 5:89–93
5. Sokka M, Parkkinen S, Pospiech H, Syväoja JE (2010) Function of
TopBP1 in genome stability. Subcell Biochem 50:119–141
6. RodriguezMC, Songyang Z (2008) BRCT domains: phosphopeptide
binding and signaling modules. Front Biosci 13:5905–5915
7. Smits VA, Warmerdam DO, Martin Y, Freire R (2010) Mechanisms
of ATR-mediated checkpoint signalling. Front Biosci 15:840–853
8. Forma E, Brzeziańska E, Krześlak A et al (2012) Association between
the c.*229C>T polymorphism of the topoisomerase IIβ binding pro-
tein 1 (TopBP1) gene and breast cancer. Mol Biol Rep 40:3493–3502
9. Bilbao C, Ramírez R, Rodríguez G et al (2010) Double strand break
repair components are frequent targets of microsatellite instability in
endometrial cancer. Eur J Cancer 46:2821–2827
10. Zighelboim I, Schmidt AP, Gao F et al (2009) ATR mutation in
endometrioid endometrial cancer is associated with poor clinical
outcomes. J Clin Oncol 27:3091–3096
11. Forma E, Krześlak A, Bernaciak M, Romanowicz-Makowska H,
Bryś M (2012) Expression of TopBP1 in hereditary breast cancer.
Mol Biol Rep 39:7795–7804
12. Liu K, Bellam N, Lin HYet al (2009) Regulation of p53 by TopBP1:
a potential mechanism for p53 inactivation in cancer. Mol Cell Biol
29:2673–2693
602 E. Forma et al.
